» Articles » PMID: 17299418

A Network Biology Approach to Prostate Cancer

Overview
Journal Mol Syst Biol
Specialty Molecular Biology
Date 2007 Feb 15
PMID 17299418
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

There is a need to identify genetic mediators of solid-tumor cancers, such as prostate cancer, where invasion and distant metastases determine the clinical outcome of the disease. Whole-genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by a condition from the hundreds to thousands of genes that exhibit changes in expression. Here, we show that reverse-engineered gene networks can be combined with expression profiles to compute the likelihood that genes and associated pathways are mediators of a disease. We apply our method to non-recurrent primary and metastatic prostate cancer data, and identify the androgen receptor gene (AR) among the top genetic mediators and the AR pathway as a highly enriched pathway for metastatic prostate cancer. These results were not obtained on the basis of expression change alone. We further demonstrate that the AR gene, in the context of the network, can be used as a marker to detect the aggressiveness of primary prostate cancers. This work shows that a network biology approach can be used advantageously to identify the genetic mediators and mediating pathways associated with a disease.

Citing Articles

Urinary marker panels for aggressive prostate cancer detection.

Lih T, Dong M, Mangold L, Partin A, Zhang H Sci Rep. 2022; 12(1):14837.

PMID: 36050450 PMC: 9437030. DOI: 10.1038/s41598-022-19134-3.


Prostate cancer screening research can benefit from network medicine: an emerging awareness.

Panebianco V, Pecoraro M, Fiscon G, Paci P, Farina L, Catalano C NPJ Syst Biol Appl. 2020; 6(1):13.

PMID: 32382028 PMC: 7206063. DOI: 10.1038/s41540-020-0133-0.


Regulation of Adipogenesis and Thermogenesis through Mouse Olfactory Receptor 23 Stimulated by α-Cedrene in 3T3-L1 Cells.

Tong T, Park J, Moon C, Park T Nutrients. 2018; 10(11).

PMID: 30453511 PMC: 6265911. DOI: 10.3390/nu10111781.


Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data.

Feng H, Li T, Zhang X BMC Genomics. 2018; 19(Suppl 6):564.

PMID: 30367578 PMC: 6101066. DOI: 10.1186/s12864-018-4925-1.


Drug Repositioning for Effective Prostate Cancer Treatment.

Turanli B, Grotli M, Boren J, Nielsen J, Uhlen M, Arga K Front Physiol. 2018; 9:500.

PMID: 29867548 PMC: 5962745. DOI: 10.3389/fphys.2018.00500.


References
1.
Basso K, Margolin A, Stolovitzky G, Klein U, Dalla-Favera R, Califano A . Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005; 37(4):382-90. DOI: 10.1038/ng1532. View

2.
Aprelikova O, Wood M, Tackett S, Chandramouli G, Barrett J . Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res. 2006; 66(11):5641-7. DOI: 10.1158/0008-5472.CAN-05-3345. View

3.
Abate-Shen C, Shen M . Molecular genetics of prostate cancer. Genes Dev. 2000; 14(19):2410-34. DOI: 10.1101/gad.819500. View

4.
Bowen C, Bubendorf L, Voeller H, Slack R, Willi N, Sauter G . Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000; 60(21):6111-5. View

5.
Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View